Calculated NOK return from USD · A (USD) (NOK Calculated)
Last NAV 589,80 USD · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+11,0 %
YTD
+13,8 %
1y
+10,2 %
3y, annualised
+9,0 %
5y, annualised
+11,9 %
10y, annualised
Fund size
321,3 mill. USD
Total fund AUM
Management fee
1,63 %
Annual · class A
Ongoing charge
1,79 %
Annual · class A
Performance fee
None
Stated by the manager
Annual cost on platforms
1,40 %–1,42 %
Class A · 3 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
May 1998
ISIN LU0085953304
BenchmarkMSCI World Health Care · Net
Risk
Volatility (stated by the manager)15,0 %
Sharpe Ratio0,43
Beta1,04
About the fund
The fund
UBS Sustainable Health Transformation Equity Fund is an actively managed healthcare equity fund with a track record going back to 1998. The management company is UBS Asset Management, the asset management division of the Swiss banking group UBS Group AG, headquartered in Zürich. The division offers both index and ETF products and active strategies.
Investment philosophy
The managers have a stated overweight in innovative small and mid-cap healthcare companies. They describe these as leaders in making healthcare more affordable, more accessible and less fragmented. The fund draws on the healthcare analysts in UBS's US intrinsic value equity team.
The managers
Matthew Konosky in Chicago has managed the fund since 2016. He is a senior analyst and portfolio manager in UBS's US intrinsic value equity team, joined UBS in 2006 from Sanford C. Bernstein, where he was a healthcare analyst, and was educated at MIT and NYU Stern. Responsibility is shared with biotech analyst Sarah Schram in Chicago, who holds a PhD in neuroscience, and Charlotte Harris in London. They are part of UBS's healthcare and biotech team and also manage UBS Biotech Equity Fund. Harris also manages UBS Small Caps Europe Equity Fund. Scott Wilkin, head of global equities at UBS, was a co-manager from 2016 until September 2026.
The portfolio
The portfolio has a large share in its largest positions and has fluctuated less than comparable funds. Alongside US companies such as Eli Lilly, UnitedHealth and Intuitive Surgical, European and Japanese companies such as AstraZeneca, Novartis, Sandoz, Alcon, Philips and Chugai Pharmaceutical recur.
FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.
7 of 18 funds ranked on a calculated return
#5/ 18Year to date
+11.02% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#6/ 221 year
+14.17% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#3/ 223 years (ann.)
+10.27% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#3/ 225 years (ann.)
+8.96% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
Comparison basis
Year to date
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
1 year
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
3 years (ann.)
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
5 years (ann.)
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.